CPIX (Cumberland Pharmaceuticals) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Cumberland Pharmaceuticals 3-Year Dividend Growth Rate?

Cumberland Pharmaceuticals's Dividends per Share for the three months ended in Sep. 2024 was $0.00.

The historical rank and industry rank for Cumberland Pharmaceuticals's 3-Year Dividend Growth Rate or its related term are showing as below:

CPIX's 3-Year Dividend Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 11.5
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Cumberland Pharmaceuticals's Dividend Payout Ratio for the three months ended in Sep. 2024 was 0.00. As of today, Cumberland Pharmaceuticals's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Cumberland Pharmaceuticals's 3-Year Dividend Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Cumberland Pharmaceuticals's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cumberland Pharmaceuticals's 3-Year Dividend Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cumberland Pharmaceuticals's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Cumberland Pharmaceuticals's 3-Year Dividend Growth Rate falls into.

Cumberland Pharmaceuticals 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Cumberland Pharmaceuticals (NAS:CPIX) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Cumberland Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Sep. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2024 )	/	EPS without NRI (Q: Sep. 2024 )
	=	0	/	-0.02
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cumberland Pharmaceuticals 3-Year Dividend Growth Rate Related Terms>

Cumberland Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cumberland Pharmaceuticals Inc (NAS:CPIX) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

1600 West End Avenue, Suite 1300, Nashville, TN, USA, 37203

Website

https://www.cumberlandpharma.com

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.

Executives

A J Kazimi	director, 10 percent owner, officer: Chairman and CEO	1207 17TH AVENUE SUITE 103, NASHVILLE TN 37212
Kenneth Krogulski	director	2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Caroline Young	director	2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
James Jones	director	2525 WEST END AVE., SUITE 950, NASHVILLE TN 37203
Todd M. Anthony	officer: Vice Pres Organizational Dev	1600 WEST END AVENUE, SUITE 1300, NASHVILLE TN 37203
Chris T. Bitterman	officer: Vice Pres Sales & Marketing	1600 WEST END AVENUE, SUITE 1300, NASHVILLE TN 37203
Joseph C Galante	director	111 TENTH AVENUE, SUITE 200, NASHVILLE TN 37203
Brown Martin S Jr	director	850 DIXIE HIGHWAY, LOUISVILLE KY 40210
Martin E Cearnal	director	31 UPPER MOUNTAIN AVENUE, APARTMENT 2, MONTCLAIR NJ 07042
John M. Hamm	officer: Chief Financial Officer	2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Gordon R Bernard	officer: Senior Vice President	2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Joey A Jacobs	director	830 CRESCENT CENTER DRIVE, SUITE 610, FRANKLIN TN 37067
Michael Bonner	officer: Chief Financial Officer	2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Jonathan Griggs	director	2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Thomas R Lawrence	director	1880 ELLINGTON WAY, AUBURN AL 36830